NHS and private care side by side
How the two routes differ
Most cancer care in the UK is delivered by the NHS, free at the point of use. Private cancer care is delivered by private hospitals, or by private units within NHS hospitals, and is paid for by insurance or by you. Cancer Research UK explains that people may go private for all of their care or just part of it, and that the main reasons are often speed and choice [1]. Those are possibilities, not promises: private care still depends on a provider having capacity and, if you are insured, your insurer agreeing to pay.
| Point | NHS route | Private route |
|---|---|---|
| Who pays | Publicly funded | Insurer, if eligible, or you |
| How you get in | GP or other NHS referral | Usually a GP or specialist referral, plus insurer approval if claiming |
| Waiting | Measured against national standards | Depends on the provider’s availability |
| Choice of specialist | Some choice, within NHS rules | Choice from the provider or insurer’s list |
| Medicines | What the NHS funds, including managed access | What your policy covers, or what you pay for |
| Records | Held by your NHS team | Held by the private provider; shared with consent |
Access to the NHS starts with a referral. The NHS explains you can ask your GP for a specialist referral, but whether you get one depends on what your GP feels is clinically needed [11]. Private specialists also usually expect a referral, and insurers almost always require one before approving a claim.
The rules for mixing NHS and private care
Many people use both routes. They might pay for an earlier private consultation and then return to the NHS for treatment, or have NHS treatment and pay privately for a medicine the NHS does not fund for them. Government guidance for the NHS in England sets the principles. Patients who choose to buy additional private care should not lose the NHS care they are entitled to, but the NHS and private parts must be kept clearly separate [6].
The guidance followed a review of access to medicines by Professor Sir Mike Richards, which is why it matters most for cancer [6]. In practice, separate means separate appointments, separate payment records and clarity about which team is responsible for what. It does not mean you have to choose one route for good.
Private patients in NHS hospitals
Some NHS hospitals have private patient units. Being treated there privately is different from being an NHS patient at the same hospital, even if the building and some staff are the same. Ask which status applies to each appointment, and make sure invoices match.
Using both NHS and private cancer care
What works well
What to watch
- Moving between teams needs careful coordination of records and results.
- Private costs can grow if one step leads to another.
- Each route has its own rules on referrals and approvals.
Moving between routes without gaps
The biggest practical risk when mixing care is a gap: results that do not reach the right team, a referral that was not made, or confusion about who is following up. A few questions asked early prevent most of these.
Step 1: Tell both teams
Let your NHS team and private specialist know you are using both routes.
Step 2: Agree who leads
Ask which team is responsible for your care at each stage, and get it in writing.
Step 3: Ask how results travel
Confirm how scan results, letters and reports will be shared, and with your consent.
Step 4: Check referrals
Ask whether moving back to the NHS needs a new referral or a letter from the private specialist.
Step 5: Separate the payments
Keep private invoices and approvals apart from NHS appointments.
Step 6: Keep your own copies
Ask for copies of key letters so you can share them if needed.
If you are insured, the insurer is a third party in this. Ask it before any private step, because moving a consultation privately does not mean later treatment will automatically be covered. Our guide to making a cancer claim covers approvals in detail.
Reading NHS cancer waiting figures
NHS England publishes monthly figures against three standards: being told within 28 days whether you have cancer after an urgent referral, starting treatment within 31 days of a decision to treat, and starting first treatment within 62 days of an urgent referral. Cancer Research UK’s analysis of the August 2026 figures reported 78.6% against the 80% target for 28 days and 92.1% against the 96% target for 31 days. For 62 days, it reported 71.9% against an 85% target that has not been met since December 2015, and said around 1,400 people, 8.9%, waited more than 104 days to start treatment [3].
- 28-day diagnosis1.4 pts
- 31-day treatment3.9 pts
- 62-day treatment13.1 pts
Cancer Research UK also notes that, in April to June 2026, people who were diagnosed with cancer were less likely to get an answer within 28 days (54.8%) than people who had cancer ruled out (79.5%) [3]. These figures describe the NHS in England overall. They cannot predict how long any one person will wait, and there is no equivalent national dataset for private cancer care. If timing drives your decision, compare an actual NHS date with an actual private date.
What stays the same on either route
Some things do not change with the route. In England, people having treatment for cancer or its effects can apply for a five-year medical exemption certificate for free NHS prescriptions [5]. Cancer is treated as a disability under the Equality Act 2010 from diagnosis [8], which matters for work and services. And the extra costs of living with cancer, such as travel and lost income, affect people on both routes; Macmillan found people with cancer were on average £570 a month worse off [4].
Macmillan’s support line is open to everyone on 0808 808 00 00, seven days a week [10]. Your NHS team can also point you to local support, whichever route you use for treatment.
Questions to ask before mixing care
A short list of questions, asked of both teams before a private step, prevents most problems. Write the answers down and keep them with your other papers.
| Ask | Question |
|---|---|
| NHS team | What happens to my NHS appointments while the private step goes ahead? |
| NHS team | Will I need a new referral to come back after private care? |
| Private provider | Will you send letters and results to my NHS team, with my consent? |
| Private provider | What exactly does your price include, and what is billed separately? |
| Insurer, if claiming | Is this private step approved, and does it affect later stages? |
Answers will differ between hospitals, so ask locally rather than relying on someone else’s experience.
If you have private insurance, add one more question for the insurer: if I move back to the NHS for part of my care, does that affect what you will pay later? Some people step in and out of private care several times, and each move is easier when the insurer knows in advance. The FCA’s Consumer Duty expects insurers to support customers in understanding their cover [2], so ask for a clear answer and keep it with your papers. A single page summarising which team is responsible for each part of your care, and who pays, is worth its weight in gold during a long treatment.
Keep that summary with your claim papers, and give a copy to anyone helping you manage appointments.
Looking at cover with PremierPMI
PremierPMI is a specialist private medical insurance broker and the publisher of The Health Guide. If you want to talk through what this means for your own cover, you can start there.
Or, if you would rather start here, send an enquiry and PremierPMI will contact you.
Common questions
Can I switch from NHS to private cancer treatment part-way through?
Will I lose my place on the NHS list if I go private?
Can I pay privately for a cancer drug the NHS won’t fund?
Is private cancer care always faster than the NHS?
Do I need a GP referral for private cancer care?
How do my NHS and private doctors share information?
Sources and methodology
- [1] Cancer Research UK. “Private cancer treatment”. View source(opens in a new tab)Primary source
- [2] Financial Conduct Authority. “The Consumer Duty”. View source(opens in a new tab)Primary source
- [3] Cancer Research UK. “Cancer waiting times: latest updates and analysis”. View source(opens in a new tab)Primary source
- [4] Macmillan Cancer Support. “Cancer – a costly diagnosis?”. View source(opens in a new tab)Primary source
- [5] NHS Business Services Authority. “Medical exemption certificates”. View source(opens in a new tab)Primary source
- [6] Department of Health and Social Care. “Guidance on NHS patients who wish to pay for additional private care”. View source(opens in a new tab)Primary source
- [7] National Institute for Health and Care Excellence. “Managed access”. View source(opens in a new tab)Primary source
- [8] legislation.gov.uk. “Equality Act 2010, Schedule 1, paragraph 6”. View source(opens in a new tab)Primary source
- [9] British Medical Association. “Access to medical reports”. View source(opens in a new tab)Primary source
- [10] Macmillan Cancer Support. “Benefits and financial support”. View source(opens in a new tab)Primary source
- [11] NHS. “Referrals for specialist care”. View source(opens in a new tab)Primary source
We cite primary sources wherever possible. Read about our sourcing methodology.

Emma Leadbetter
Editor and Copywriter, PremierPMI
- 15 years health, finance and consumer journalism
- PhD candidate, University of Chichester
Emma has written across health, finance and consumer-affairs journalism for more than 15 years, and has been part of the PremierPMI team since 2022. She is known for making complex topics easy to understand, and fact-checks every guide against current insurer wording before it goes live. She is completing a PhD at the University of Chichester researching how the NHS has changed since COVID-19.
Read full profile
Parvoz Haydarov
Founder, PremierPMI
- Founder of PremierPMI
- Whole-of-market private medical insurance
Parvoz founded PremierPMI as a specialist private medical insurance brokerage. He sets the direction of the firm — insurer relationships, service standards, compliance culture and the editorial bar for everything published under the PremierPMI name — and personally reviews the largest corporate and family cases before they go to market.
Read full profile






